LabGenius raises £11.6m in a Series A extension led by Atomico to scale its drug discovery platform.
The funding round was led by Atomico with participation from Lux Capital, Obvious Ventures, Kindred Capital and Inovia Capital.
LabGenius develops machine learning-driven protein engineering platforms to discover next-generation therapeutics. The London-based company uses robotic automation and synthetic biology to improve drug discovery.
LabGenius has secured £11.6m in a Series A extension round led by Atomico, bringing its total Series A financing to $25m. The company will direct the capital towards scaling its discovery platform and advancing its therapeutic pipeline.
Existing backers Lux Capital, Obvious Ventures, Kindred Capital and Inovia Capital also participated in the financing. Alongside the investment, Atomico Partner Irina Haivas will join the company board.
Founded to address productivity bottlenecks in pharmaceutical research, LabGenius combines robotic automation and synthetic biology in a closed loop system. The approach allows the team to evaluate billions of protein designs rapidly.
From the founder
"To add a fund of Atomico’s calibre and reputation to our investor base is a huge win for LabGenius. Atomico’s operational experience is second to none and they are the perfect partner to help us scale a global company from Europe. In addition, the confidence that Lux, Obvious, Kindred and Inovia have demonstrated in doubling down in this round reflects the tremendous technical progress that the team has made over the past 12 months."
James Field
Founder and CEO at LabGenius
Use of funds
- 01Fund research and development
